STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2004 KENTUCKY

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS. BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY. BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b} NONDUAL BENEFICIARIES, KENTUCKY, 2004

			Number of Be	neficiaries				1	Number of Ben	efit Months		
Beneficiary						Other/	,					Other/
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	531,006	1,399	112,038	101,837	315,366	366	5,047,400	9,343	1,223,321	778,539	3,035,019	1,178
Age												
5 and younger	125,913	1	4,039	13	121,860	0	1,168,426	12	43,768	72	1,124,574	0
6-14	150,227	0	13,058	25	137,144	0	1,530,277	0	148,281	154	1,381,842	0
15-20	75,863	0	9,624	10,477	55,761	1	709,280	0	106,199	77,680	525,399	2
21-44	124,942	4	38,673	85,470	556	239	1,084,582	36	426,242	654,733	2,903	668
45-64	51,992	22	45,977	5,847	21	125	539,045	197	492,376	45,872	96	504
65-74	825	268	555	2	0	0	7,265	1,905	5,345	15	0	0
75-84	627	534	92	1	0	0	4,804	3,846	951	7	0	0
85 and older	592	570	20	2	0	0	3,512	3,347	159	6	0	0
Unknown	25	0	0	0	24	1	209	0	0	0	205	4
Gender												
Female	301,760	797	58,775	86,701	155,121	366	2,815,333	4,884	646,957	664,719	1,497,595	1,178
Male	229,244	601	53,262	15,136	160,245	0	2,232,049	4,453	576,352	113,820	1,537,424	0
Unknown	2	1	1	0	0	0	18	6	12	0	0	0
Race												
White	454,259	1,188	85,592	90,613	276,523	343	4,311,783	7,663	933,964	701,897	2,667,171	1,088
African American	42,223	98	5,367	8,174	28,566	18	398,888	673	56,547	64,951	276,643	74
Other/unknown	34,524	113	21,079	3,050	10,277	5	336,729	1,007	232,810	11,691	91,205	16
Use of Nursing Facilities ^c												
Entire year	1,128	307	807	10	4	0	11,271	2,959	8,242	22	48	0
Part year	3,058	150	2,426	470	12	0	31,329	1,324	25,342	4,525	138	0
None	526,820	942	108,805	101,357	315,350	366	5,004,800	5,060	1,189,737	773,992	3,034,833	1,178
Maintenance Assistance Status												
Cash	248,859	236	107,896	51,016	89,711	0	2,538,473	2,326	1,197,388	430,941	907,818	0
Medically needy	21,132	201	2,566	10,529	7,836	0	163,606	1,101	10,912	74,486	77,107	0
Poverty-related	220,442	16	22	27,101	192,937	366	1,953,212	156	147	156,374	1,795,357	1,178
Other/unknown	40,573	946	1,554	13,191	24,882	0	392,109	5,760	14,874	116,738	254,737	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	525,995	1,377	110,686	100,725	312,847	360	5,024,554	9,252	1,216,204	775,076	3,022,855	1,167
FFS part year, with Rx claims	2,809	14	1,044	460	1,287	4	15,954	72	5,987	2,239	7,648	8
FFS part year, no Rx claims	2,202	8	308	652	1,232	2	6,892	19	1,130	1,224	4,516	3

Table ND2 Nondual Beneficiaries

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3 ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{9, b} NONDUAL BENEFICIARIES, KENTUCKY, 2004

Beneficiary	Percentage with at	Mean Number			Mean \$, All Medicaid	Rx \$ as a Percentage of All Medicaid	Number of
Characteristics	Least One Rx	of Rx	Mean Rx \$	\$ per Rx	FFS \$°	FFS \$ ^d	Beneficiaries
All	76.2 %	13.8	\$804	\$58	\$3,771	21.3 %	531,006
Age							
5 and younger	74.3	5.8	300	52	2,067	14.5	125,913
6-14	72.5	6.9	438	64	2,100	20.9	150,227
15-20	73.8	7.8	468	60	3,343	14.0	75,863
21-44	80.0	17.3	996	58	4,913	20.3	124,942
45-64	85.9	52.4	3,060	58	10,198	30.0	51,992
65-74	72.6	48.8	2,536	52	15,153	16.7	825
75-84	63.8	45.3	2,203	49	15,296	14.4	627
85 and older	47.3	33.7	1,406	42	12,022	11.7	592
Unknown	68.0	4.4	405	92	1,886	21.4	25
Basis of Eligibility ^e							
Aged	53.6	37.0	1,739	47	12,963	13.4	1,399
Disabled	85.9	38.6	2,498	65	9,551	26.2	112,038
Adults	77.8	10.9	487	45	3,227	15.1	101,837
Children	72.3	5.8	300	52	1,849	16.2	315,366
Unknown	77.6	8.4	1,013	120	7,439	13.6	366
Gender							
Female	78.4	15.6	853	55	3,906	21.8	301,760
Male	73.2	11.5	740	64	3,595	20.6	229,244
Unknown	50.0	35.5	1,178	33	4,494	26.2	2
Race							
White	77.4	13.7	784	57	3,633	21.6	454,259
African American	64.8	7.5	445	59	3,195	13.9	42,223
Other/unknown	74.1	22.6	1,507	67	6,300	23.9	34,524
Use of Nursing							
Facilities ^f							
Entire year	97.3	119.0	6,405	54	57,070	11.2	1,128
Part year	96.9	65.2	4,444	68	32,084	13.9	3,058
None	76.0	13.3	771	58	3,493	22.1	526,820
Maintenance Assistance Status							
Cash	80.9	21.8	1,325	61	5,265	25.2	248,859
Medically needy	68.4	11.1	590	53	3,970	14.9	21,132
Poverty related	71.3	5.4	262	48	1,832	14.3	220,442
Other/unknown	77.6	11.6	672	58	5,050	13.3	40,573

Table ND3 Nondual Beneficiaries

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving fost care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, KENTUCKY, 2004

					N	umber of Rx, Per	centage with:			_	Numb	er
Beneficiary Characteristics	Mean Number of Rx	A Mean Rx \$	Rx \$ as a centage of II Medicaid FFS \$ ^c	None	0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than	Mean \$, All Medicaid FFS \$ ^d	Beneficiaries	Benefit Months
All	1.5	\$85	21.3 %	23.8 %	52.1 %	9.3 %	9.2 %	4.2 %	1.4 %	\$397	531,006	5,047,400
Age												
5 and younger	0.6	32	14.5	25.7	64.3	6.9	2.8	0.2	0.0	223	125,913	1,168,426
6-14	0.7	43	20.9	27.5	59.9	7.1	4.9	0.5	0.1	206	150,227	1,530,277
15-20	0.8	50	14.0	26.2	57.4	9.5	5.9	0.9	0.1	358	75,863	709,280
21-44	2.0	115	20.3	20.0	43.2	14.0	15.8	5.7	1.3	566	124,942	1,084,582
45-64	5.1	295	30.0	14.1	15.2	9.8	25.5	24.7	10.7	984	51,992	539,045
65-74	5.5	288	16.7	27.4	9.2	5.5	20.2	24.2	13.5	1,721	825	7,265
75-84	5.9	288	14.4	36.2	6.5	4.8	15.9	23.0	13.6	1,996	627	4,804
85 and older	5.7	237	11.7	52.7	3.4	4.1	10.6	18.8	10.5	2,026	592	3,512
Unknown	0.5	48	21.4	32.0	60.0	8.0	0.0	0.0	0.0	226	25	209
Basis of Eligibility ^e												
Aged	5.5	260	13.4	46.4	5.3	4.6	13.1	19.7	10.9	1,941	1,399	9,343
Disabled	3.5	229	26.2	14.1	28.1	12.2	23.1	16.2	6.3	875	112,038	1,223,321
Adults	1.4	64	15.1	22.2	48.8	13.9	11.8	2.8	0.4	422	101,837	778,539
Children	0.6	31	16.2	27.7	61.9	6.7	3.4	0.3	0.0	192	315,366	3,035,019
Unknown	2.6	315	13.6	22.4	28.4	16.4	22.1	6.8	3.8	2,311	366	1,178
Gender												
Female	1.7	91	21.8	21.6	51.5	10.0	10.1	5.0	1.8	419	301,760	2,815,333
Male	1.2	76	20.6	26.8	52.9	8.3	8.0	3.1	0.9	369	229,244	2,232,049
Unknown	3.9	131	26.2	50.0	0.0	0.0	0.0	0.0	50.0	499	2	18
Race												
White	1.4	83	21.6	22.6	53.2	9.5	9.2	4.1	1.4	383	454,259	4,311,783
African American	0.8	47	13.9	35.2	51.9	6.0	4.6	1.7	0.6	338	42,223	398,888
Other/unknown	2.3	155	23.9	25.9	38.1	10.0	14.4	8.4	3.1	646	34,524	336,729
Use of Nursing Facilities ^f												
Entire year	11.9	641	11.2	2.7	2.0	1.9	12.7	30.6	50.1	5,712	1,128	11,271
Part year	6.4	434	13.9	3.1	14.1	10.3	24.9	28.9	18.6	3,132	3,058	31,329
None	1.4	81	22.1	24.0	52.4	9.3	9.1	4.0	1.2	368	526,820	5,004,800
Maintenance Assistance Status												
Cash	2.1	130	25.2	19.1	45.2	10.7	14.2	8.0	2.8	516	248,859	2,538,473
Medically needy	1.4	76	14.9	31.6	41.5	10.3	11.6	4.1	0.9	513	21,132	163,606
Poverty related	0.6	30	14.3	28.7	60.3	7.3	3.4	0.3	0.0	207	220,442	1,953,212
Other/unknown	1.2	70	13.3	22.4	55.0	10.4	8.8	2.4	1.0	523	40,573	392,109

Table ND4 Nondual Beneficiaries

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{6, b, c}

NONDUAL BENEFICIARIES, KENTUCKY, 2004

Beneficiary		All Rx		Patented Br	and-Name	Drugs	Off-Patent B	rand-Name	Drugs	Gen	eric Drugs	
_	Number			Number			Number			Number		
Beneficiary Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	1.5	\$85	\$58	0.6	\$62	\$109	0.1	\$5	\$66	0.8	\$17	\$21
Age												
5 and younger	0.6	32	52	0.2	25	102	0.1	2	39	0.3	5	16
6-14	0.7	43	64	0.3	35	102	0.0	2	55	0.3	6	21
15-20	0.8	50	60	0.3	37	110	0.0	2	58	0.5	11	23
21-44	2.0	115	58	0.7	81	117	0.1	8	76	1.2	25	21
45-64	5.1	295	58	1.9	211	110	0.3	20	76	2.9	64	22
65-74	5.5	288	52	2.0	200	98	0.3	19	62	3.2	68	22
75-84	5.9	288	49	2.2	202	92	0.3	15	47	3.4	70	21
85 and older	5.7	237	42	2.0	160	79	0.4	15	42	3.3	62	19
Unknown	0.5	48	92	0.2	42	219	0.0	1	30	0.3	5	18
Basis of Eligibility ^d												
Aged	5.5	260	47	2.1	182	87	0.3	15	47	3.1	63	20
Disabled	3.5	229	65	1.4	168	122	0.2	15	79	2.0	45	23
Adults	1.4	64	45	0.5	43	91	0.1	4	59	0.9	16	18
Children	0.6	31	52	0.3	24	92	0.0	2	44	0.3	6	19
Unknown	2.6	315	120	0.6	254	397	0.1	5	52	1.9	56	30
Gender												
Female	1.7	91	55	0.6	66	105	0.1	6	63	0.9	19	21
Male	1.2	76	64	0.5	57	117	0.1	5	71	0.6	14	23
Unknown	3.9	131	33	1.3	81	63	0.3	5	18	2.4	45	19
Race												
White	1.4	83	57	0.6	60	108	0.1	5	66	0.8	17	21
African American	0.8	47	59	0.3	36	114	0.0	3	58	0.4	9	20
Other/unknown	2.3	155	67	1.0	118	121	0.1	9	73	1.2	27	23
Use of Nursing Facilities ^e												
Entire year	11.9	641	54	3.7	412	111	0.8	42	55	7.4	186	25
Part year	6.4	434	68	2.3	321	137	0.4	28	78	3.6	85	23
None	1.4	81	58	0.5	60	109	0.1	5	66	0.8	16	21
Maintenance Assistance Status												
Cash	2.1	130	61	0.8	95	115	0.1	9	73	1.2	26	22
Medically needy	1.4	76	53	0.5	54	103	0.1	5	65	0.8	17	21
Poverty related	0.6	30	48	0.2	22	88	0.0	2	43	0.3	6	18
Other/unknown	1.2	70	58	0.5	53	106	0.1	4	56	0.6	13	20

Table ND5 Nondual Beneficiaries

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Kentucky, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}

NONDUAL BENEFICIARIES, KENTUCKY, 2004

		er of Rx	•		\$ per E	Benefit M Use		nong		\$ pe	r Rx			_		Users ^e	
Therapeutic Category	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.3	0.1	0.0	0.2	\$13	\$9	\$1	\$3	\$46	\$76	\$57	\$22	928,666	\$42,425,556	305,994	57.6 %	3,237,732
Biologicals	0.4	0.4	0.0	0.0	458	412	3	43	1155	1,091	1,331	2,539	7,837	9,050,170	2,068	0.4	19,781
Antineoplastic Agents	0.6	0.2	0.0	0.4	216	158	23	36	363	1,050	553	88	15,818	5,737,748	2,559	0.5	26,559
Endocrine/Metabolic Drugs	0.5	0.2	0.1	0.2	26	19	2	5	51	94	32	20	589,648	30,063,589	108,965	20.5	1,162,687
Cardiovascular Agents	1.3	0.5	0.0	8.0	50	36	1	13	38	72	36	17	986,609	37,483,532	68,303	12.9	746,133
Respiratory Agents	0.5	0.2	0.0	0.2	27	21	1	4	54	90	33	20	1,201,354	65,281,587	227,870	42.9	2,452,186
Gastrointestinal Agents	0.4	0.1	0.0	0.3	24	16	1	6	53	142	76	20	395,475	21,090,804	81,109	15.3	881,927
Genitourinary Agents	0.3	0.1	0.0	0.1	15	10	2	3	57	80	48	32	86,916	4,940,585	32,460	6.1	337,706
CNS Drugs	0.8	0.4	0.0	0.4	71	58	3	10	86	145	80	26	921,064	78,880,007	103,122	19.4	1,106,414
Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/	0.7	0.6	0.0	0.1	58	53	0	4	85	92	69	45	200,628	17,041,876	26,560	5.0	292,806
Neurological Agents	0.5	0.5	0.0	0.0	173	172	0	1	316	339	0	17	8,070	2,553,991	1,364	0.3	14,751
Analgesics and Anesthetics	0.4	0.1	0.0	0.3	16	10	0	5	36	113	203	14	844,647	30,037,523	183,332	34.5	1,935,389
Neuromuscular Agents	0.7	0.2	0.1	0.4	54	30	13	11	81	147	130	30	520,364	42,162,335	72,077	13.6	782,641
Nutritional Products	0.4	0.1	0.0	0.3	10	2	0	7	22	25	21	22	128,764	2,852,423	30,722	5.8	296,492
Hematological Agents	0.7	0.3	0.0	0.3	118	100	3	15	175	334	95	43	97,814	17,109,642	13,488	2.5	145,350
Topical Products	0.2	0.1	0.0	0.1	10	7	0	3	48	91	59	21	360,052	17,352,940	155,788	29.3	1,683,125
Miscellaneous Products	0.5	0.1	0.0	0.3	72	47	8	17	154	449	289	51	15,840	2,443,071	3,266	0.6	33,713
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	5	0	0	0	20	0	0	0	22,500	455,344	8,923	1.7	99,776
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	7,332,066	426,962,723	n.a.	n.a.	n.a.

- a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Kentucky, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c} NONDUAL BENEFICIARIES, KENTUCKY, 2004

			Users		Ar	mong Users	
Top 10 Drug Groups	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	Rx : \$ per Rx	\$ per Benefit Month
ANTIASTHMATIC	\$43,742,139	161,195	30.4 %	1,783,722	0.3	\$74	\$25
ANTIPSYCHOTICS	43,575,242	36,605	6.9	411,035	0.5	203	106
ANTICONVULSANT	33,544,448	51,855	9.8	574,374	0.6	97	58
ANTIDEPRESSANTS	31,828,026	111,966	21.1	1,216,140	0.5	58	26
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	16,963,064	32,746	6.2	366,430	0.5	85	46
ANTIHYPERLIPIDEMIC	16,540,109	30,697	5.8	348,550	0.6	81	47
ULCER DRUGS	16,451,090	90,414	17.0	996,502	0.4	46	17
ANTIDIABETIC	16,061,647	34,985	6.6	390,110	0.6	67	41
ANALGESICS - Narcotic	14,696,111	177,936	33.5	1,885,921	0.2	34	8
DERMATOLOGICAL	12,108,355	150,581	28.4	1,661,046	0.2	47	7
Total	245,510,231	878,980		9,633,830	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Kentucky, released by CMS in 02/2008. This table was produced on 03/06/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7 Nondual Beneficiaries

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.7A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED

AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{8, b, c}

NONDUAL BENEFICIARIES, KENTUCKY, 2004

	All Top 10 Dr	ug Groups		ANTIA	STHMATIC				ANTIPS	SYCHOTICS		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Rx \$ per
All	3,395,034	\$245,510,231	161,195	30.4 %	1,783,722	0.3	\$25	36,605	6.9 %	411,035	0.5	\$106
Female	2,107,838	145,700,058	90,442	30.0	1,000,093	0.3	25	19,997	6.6	223,740	0.5	97
Disabled	1,380,461	103,673,109	38,711	65.9	448,574	0.5	35	13,435	22.9	154,827	0.6	115
E and variance	9,222	793,814	1,091	69.6	12,731	0.3	30	32	2.0	375	0.5	70
5 and younger	41,527	3,986,556	1,728	41.0	20,309	0.3	28	795	18.9	9,221	0.6	106
6-14	33,349	3,056,393	1,091	31.4	12,656	0.3	24	757	21.8	8,794	0.5	99
15-20	420,024	33,428,687	11,417	53.9	133,072	0.4	28	5,838	27.5	67,407	0.5	108
21-44	865,361	61,721,781	23,065	82.6	266,536	0.5	39	5,923	21.2	68,057	0.6	127
45-64	9,334	587,230	261	77.4	2,713	0.5	47	71	21.1	762	0.6	99
65-74	1,411	84,876	52	96.3	485	0.5	38	16	29.6	179	0.6	67
75-84	233	13,772	6	46.2	72	0.7	49	3	23.1	32	0.5	75
85 and older Other Eligibles	727,363	42,025,335	51,728	21.3	551,483	0.2	17	6,562	2.7	68,913	0.4	57
_	81,705	4,585,388	16,407	27.8	178,512	0.2	17	166	0.3	1,899	0.4	64
5 and younger	153,451	10,250,812	14,966	22.0	167,468	0.3	18	1,630	2.4	18,475	0.4	71
6-14	97,919	5,562,135	6,402	16.9	68,205	0.2	14	1,291	3.4	13,916	0.4	61
15-20	345,376	18,603,520	12,476	17.0	122,474	0.3	16	3,119	4.2	31,050	0.3	
21-44	40,131	2,550,952	1,321	34.7	13,266	0.4	26	241	6.3	2,426	0.4	
45-64	2,036	135,064	35	23.8	347	0.5	31	24	16.3	256	0.8	
65-74	4,193	223,336	76	25.5	782	0.5	36	45	15.1	467	0.6	
75-84	2,552	114,128	45	13.3	429	0.5	21	46	13.6	424	0.5	
85 and older	2,002	114,120	40	10.0	423	0.0	21	40	10.0	727	0.0	00
Male	1,287,171	99,809,319	70,752	30.9	783,623	0.3	24	16,606	7.2	187,283	0.6	116
Disabled	814,452	66,227,949	22,485	42.2	258,598	0.5	34	11,182	21.0	127,708	0.6	131
F d	15,506	1,356,131	1,921	77.7	22,264	0.3	28	141	5.7	1,659	0.4	78
5 and younger	104,854	10,179,306	3,674	41.5	43,174	0.3	27	2,614	29.6	30,402	0.6	107
6-14	52,921	5,473,021	1,456	23.7	16,936	0.3	26	1,522	24.7	17,470	0.5	118
15-20	232,314	20,050,615	4,253	24.3	49,235	0.4	28	3,976	22.7	45,177	0.6	147
21-44	402,847	28,774,989	10,945	60.6	124,538	0.6	40	2,879	15.9	32,465	0.6	142
45-64	4,916	315,710	198	90.8	2,027	0.7	51	35	16.1	361	0.6	73
65-74	990	72,379	33	86.8	372	0.5	32	15	39.5	174	0.6	144
75-84	104	5,798	5	71.4	52	0.4	23	0	0.0	0	0.0	0
85 and older Other Eligibles	472,713	33,580,869	48,263	27.4	524,988	0.2	19	5,424	3.1	59,575	0.5	85
_	97,221	6,245,569	22,333	35.5	240,922	0.2	18	307	0.5	3,502	0.4	67
5 and younger	213,949	16,455,916	19,144	27.7	213,029	0.3	20	3,094	4.5	34,775	0.5	86
6-14	70,492	5,378,220	4,360	15.3	47,333	0.3	18	1,279	4.5	14,101	0.5	92
15-20	60,380	3,565,446	1,640	12.8	16,122	0.3	23	492	3.9	4,661	0.3	60
21-44	18,827	1,269,283	551	24.9	5,303	0.4	31	101	4.6	995	0.5	81
45-64	1,835	127,423	46	37.4	386	0.4	25	31	25.2	346	0.6	
65-74	5,442	313,554	95	40.1	1,045	0.6	32	75	31.6	756	0.7	108
75-84	4,567	225,458	94	40.3	848	0.6	29	45	19.3	439	0.7	
85 and older	1,307	223, 130	5 4	10.0	040	0.0		10	10.0	700	0.7	30
Unknown	45	2,969	8	29.6	79	0.2	23	2	7.4	12	0.5	36

Table ND7A Nondual Beneficiaries

- a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7A Nondual Beneficiaries

TABLE ND.7B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

NONDUAL BENEFICIARIES, KENTUCKY, 2004

		ANTICC	NVULSANT				ANTIDE	PRESSANTS			STIMULA	NTS/ANTI-	OBESITY/ANG	OREXIAN	ITS
		Users as %	Number of Benefit Months	of Rx	Mean Rx \$ per		Users as %	Number of Benefit Months	of Rx	Mean Rx \$ per		Users as %	Number of Benefit Months	of Rx	Mean Rx \$ per
Beneficiary	Number of	of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
All	51,855	9.8 %	574,374	0.6	\$58	111,966	21.1 %	1,216,140	0.5	\$26	32,746	6.2 %	366,430	0.5	\$46
Female	33,843	11.2	374,291	0.6	56	81,027	26.9	874,262	0.4	27	10,205	3.4	114,265	0.5	
Disabled	22,071	37.6	254,607	0.7	64	43,109	73.3	497,358	0.5	32	2,970	5.1	34,543	0.5	50
5 and younger	216	13.8	2,466	0.7	98	24	1.5	270	0.5	14	81	5.2	960	0.4	30
6-14	882	20.9	10,231	0.7	102	846	20.1	9,889	0.5	22	1,485	35.2	17,307	0.6	49
15-20	910	26.2	10,468	0.7	87	1,399	40.3	16,300	0.4	24	412	11.9	4,807	0.5	49
21-44	9,574	45.2	110,683	0.6	63	17,372	82.0	200,722	0.5	29	548	2.6	6,369	0.4	52
45-64	10,399 84	37.2 24.9	119,773 921	0.7 0.6	59 39	23,269 172	83.3	268,054	0.6 0.7	34 33	441 3	1.6 0.9	5,069 31	0.4 0.2	59 14
65-74	84 4	24.9 7.4	921 41	0.8	39 34	23	51.0 42.6	1,842	0.7	33 27	0	0.9	0	0.2	
75-84	2	7. 4 15.4	24		78	23 4	30.8	239 42	0.6	36	0	0.0	0	0.0	0
85 and older Other Eligibles	11,772	4.8	119.684	0.5 0.4	76 39	37,917	30.6 15.6	376.892	0.8	20	7,235	3.0	79.722	0.0	42
Other Eligibles	266	0.5	2,916	0.4	39	148	0.3	1,706	0.3	10	7,233 453	0.8	5,088	0.3	24
5 and younger	1,109	1.6	12,403	0.4	52	3.182	4.7	35,653	0.3	17	5,053	7.4	56,284	0.5	43
6-14	1,430	3.8	15,108	0.4	47	6.196	16.4	64,820	0.4	17	899	2.4	9.839	0.5	41
15-20	8,181	11.1	81,540	0.4	35	26,094	35.5	252,629	0.3	21	776	1.1	7,966	0.4	45
21-44	696	18.3	6,827	0.5	46	2,081	54.7	19,924	0.5	29	51	1.3	518	0.4	51
45-64	30	20.4	330	0.8	44	43	29.3	462	0.7	42	1	0.7	12	0.3	22
65-74	33	11.1	299	1.0	41	92	30.9	890	0.9	42	2	0.7	15	1.3	53
75-84	27	8.0	261	0.8	40	81	24.0	808	0.8	38	0	0.0	0	0.0	
85 and older															
Male	18,012	7.9	200,083	0.6	63	30,938	13.5	341,872	0.5	25	22,541	9.8	252,165	0.6	47
Disabled	13,515	25.4	153,682	0.7	68	20,280	38.1	231,158	0.5	27	7,412	13.9	86,144	0.6	52
5 and younger	311	12.6	3,517	0.7	92	86	3.5	944	0.4	11	354	14.3	4,137	0.4	29
6-14	1,587	17.9	18,335	0.7	86	1,995	22.6	23,331	0.5	22	5,298	59.9	61,794	0.6	53
15-20	1,156	18.8	13,241	0.7	90	1,634	26.6	18,700	0.5	26	1,379	22.4	15,926	0.6	53
21-44	5,532	31.7	63,049	0.7	68	7,805	44.7	88,687	0.5	27	277	1.6	3,108	0.5	48
45-64	4,872	27.0	54,962	0.7	56 50	8,677	48.1	98,627 689	0.5	29	104 0	0.6	1,179	0.4	55
65-74	43 12	19.7 31.6	424 141	0.8 0.9	52 29	67 13	30.7 34.2	144	0.6 0.9	25 36	0	0.0 0.0	0	0.0	0
75-84	2	28.6	13	1.6	171	3	42.9	36	0.9	28	0	0.0	0	0.0	0
85 and older Other Eligibles	4,497	2.6	46,401	0.5	44	10,658	6.1	110,714	0.4	20	15,129	8.6	166,021	0.5	45
Otner Eligibles	4,497 314	0.5	3,426	0.5	31	169	0.3	1,904	0.4	9	1,071	1.7	12,048	0.3	25
5 and younger	1,457	2.1	16,336	0.4	49	3,650	5.3	40,774	0.3	18	12,000	17.4	131,772	0.4	46
6-14	770	2.7	8,149	0.5	56	2,690	9.5	28,554	0.4	21	1,956	6.9	21,232	0.5	46
15-20	1,513	11.8	14,259	0.4	35	3,174	24.8	30,117	0.4	20	85	0.7	803	0.4	50
21-44	334	15.1	3,071	0.5	47	735	33.2	6,920	0.4	26	14	0.6	141	0.5	60
45-64	22	17.9	241	0.7	48	37	30.1	400	0.9	42	0	0.0	0	0.0	0
65-74	49	20.7	527	0.9	49	106	44.7	1,114	0.9	42	0	0.0	0	0.0	0
75-84	38	16.3	392	0.5	23	97	41.6	931	0.9	40	3	1.3	25	0.7	47
85 and older											_				
Unknown	0	0.0	0	0.0	0	2	7.4	18	0.6	21	0	0.0	0	0.0	0

Table ND7B Nondual Beneficiaries

- a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7B Nondual Beneficiaries

TABLE ND.7C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
NONDUAL BENEFICIARIES, KENTUCKY, 2004

		ANTIHYF	PERLIPIDEMIC)			ULCE	R DRUGS				ANTI	DIABETIC		
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Rx \$ per Benefit Month
All	30,697	5.8 %	348,550	0.6	\$48	90,414	17.0 %	996,502	0.4	\$17	34,985	6.6 %	390,110	0.6	\$41
Female	19,664	6.5	223,980	0.6	47	60,526	20.1	666,890	0.4	16	24,088	8.0	268,669	0.6	
Disabled	16,626	28.3	193,122	0.6	49	34,093	58.0	396,562	0.4	20	18,943	32.2	218,349	0.6	42
5 and younger	4 12	0.3	48	0.1	3 32	269 530	17.2	2,990	0.4	21	7	0.4	84	0.5	33 52
6-14	22	0.3 0.6	138 251	0.5 0.5	32 46	768	12.6 22.1	6,263 8,923	0.3	20 13	89 171	2.1 4.9	1,009 1,998	0.7 0.5	38
15-20	3.248	15.3	37.906	0.5	39	11.606	54.8	135,576	0.3	13 17	4.149	4.9 19.6	48.164	0.5	38
21-44	13,167	47.2	152,889	0.6	59 51	20,648	74.0	239,851	0.4	22	14,295	51.2	164,658	0.6	44
45-64	13,107	43.3	1,592	0.6	54	20,048	67.4	2,462	0.5	22	206	61.1	2,153	0.8	44
65-74	25	46.3	274	0.0	60	39	72.2	433	0.6	21	25	46.3	2,133	0.8	41
75-84	2	15.4	24	0.8	85	6	46.2	64	0.9	15	1	7.7	12	0.3	8
85 and older Other Eligibles	3.038	1.3	30.858	0.4	33	26.432	10.9	270,318	0.2	11	5.145	2.1	50,320	0.5	32
Other Eligibles	31	0.1	315	0.2	6	2,296	3.9	21,844	0.2	8	42	0.1	456	0.8	46
5 and younger	35	0.1	394	0.3	18	4,061	6.0	45,869	0.2	8	398	0.6	4,465	0.7	48
6-14	106	0.3	1,160	0.2	15	4,717	12.5	50,195	0.2	7	559	1.5	5,761	0.5	32
15-20	2,052	2.8	20,921	0.4	31	13,798	18.8	136,709	0.3	12	3,260	4.4	31,045	0.5	29
21-44	728	19.1	7,189	0.5	42	1,378	36.2	13,841	0.4	19	718	18.9	6,940	0.5	
45-64	33	22.4	353	0.6	49	45	30.6	468	0.5	27	53	36.1	554	0.6	37
65-74	49	16.4	488	0.7	55	72	24.2	743	0.6	29	82	27.5	755	0.7	30
75-84	4	1.2	38	0.4	30	65	19.2	649	0.6	22	33	9.8	344	0.6	28
85 and older	44.000						40.0								
Male	11,033	4.8	124,570	0.6	49	29,888	13.0	329,612	0.4	17	10,897	4.8	121,441	0.6	43
Disabled	9,446	17.7	108,957	0.6	51	17,840	33.5	205,188	0.5	20	9,069	17.0	103,406	0.6	43
5 and younger	3	0.1	25	0.2	2	314	12.7	3,492	0.4	24	16	0.6	156	0.7	70
6-14	10	0.1	111	0.4	32	789	8.9	9,292	0.3	16	97	1.1	1,094	0.8	59
15-20	35	0.6	392	0.5	31	864	14.0	10,068	0.3	15	109	1.8	1,252	0.7	51
21-44	2,319 7,007	13.3	26,905	0.5 0.7	43 53	6,028	34.5	69,657	0.4	19	2,103	12.0	24,064	0.6	40
45-64	7,007 67	38.8 30.7	80,770 694	0.7	56	9,690 123	53.7 56.4	111,072 1,263	0.5 0.5	22 22	6,620 110	36.7 50.5	75,561 1,125	0.7 0.7	44 39
65-74	4	10.5	48	1.0	93	27	71.1	286	0.5	29	110	28.9	1,125	0.7	56
75-84	1	14.3	12	1.0	95 25	5	71.1	58	0.3	29 15	3	42.9	30	0.8	
85 and older Other Eligibles	1,587	0.9	15,613	0.5	38	12,048	6.8	124,424	0.3	11	1,828	1.0	18,035	0.2	
Other Eligibles	33	0.5	344	0.2	8	2,752	4.4	26,440	0.2	9	54	0.1	623	0.7	46
5 and younger	39	0.1	451	0.4	28	3,582	5.2	40,142	0.2	9	249	0.4	2,698	0.7	58
6-14	74	0.1	810	0.4	20	2,349	8.3	25,340	0.2	8	208	0.7	2,090	0.7	65
15-20	855	6.7	8,253	0.5	36	2,476	19.4	23,625	0.2	17	788	6.2	7,354	0.7	
21-44	511	23.1	4,957	0.5	45	654	29.6	6,402	0.4	22	380	17.2	3.645	0.6	38
45-64	21	17.1	216	0.7	52	38	30.9	384	0.5	18	29	23.6	274	0.8	35
65-74	31	13.1	351	0.7	53	103	43.5	1,108	0.6	33	53	22.4	584	0.8	37
75-84	23	9.9	231	0.8	55	94	40.3	983	0.6	37	67	28.8	677	0.8	43
85 and older															
Unknown	0	0.0	0	0.0	0	1	3.7	10	0.1	6	0	0.0	0	0.0	0

Table ND7C Nondual Beneficiaries

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7C Nondual Beneficiaries

TABLE ND.7D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, KENTUCKY, 2004

Part			ANALGES	SICS - Narcoti	С			DERMA	TOLOGICAL				
Female	Characteristics	Users	as % of All Benes	Benefit Months Among Users	Number of Rx per Benefit Month	Rx \$ per Benefit Month	Users	as % of All Benes	Benefit Months Among Users	Number of Rx per Benefit Month	Rx \$ per Benefit Month	Beneficiaries	Benefit Months
Disabled	Famala	,			0.2	•	,				·	,	
Sand younger												,	
6 and younger 560 1.3.3 6.615 0.1 1 1.912 45.4 22.521 0.2 6 4.215 3.78 3.86 15.20 1.635 47.1 19.125 0.2 2 1.269 3.65 14.9855 0.1 7 3.473 3.86 15.20 1.21 21.195 236.7 1.21 21.195 236.7 1.21 21.195 236.7 2.11 2.21 21.195 236.7 3.86 1.22 21.195 236.7 3.83 3.77.90 3.02 127.193 0.2 13 27.7920 302.9 302.9 127.193 0.2 13 27.7920 302.9 302.9 127.193 0.2 13 27.920 302.9 302.9 127.193 0.2 13 27.920 302.9 302.9 127.193 0.2 13 27.920 302.9 302.9 127.193 0.2 13 327.920 302.9 302.9 120.0 0.3 7 13 15.20 15.20	Disabled	,					,		,			,	,
6-14	5 and younger						-					*	,
15-20						-							•
21-44 4	15-20	,					,					,	
45-64	21-44	,		,			,		,			,	•
65-74 75-84 75-84 75-86	45-64	,		,			,		,			,	•
75-84	65-74				• • •								,
65 and older 5 88.5 52 0.4 10 10 69 10 69 120 12 0 68 90 120 7 13 5 30 120 Other Eligibles 76,460 31.5 750,065 0.2 4 68,900 28.4 742,822 0.1 6 242,973 2,188,2 5 and younger 6,167 9.1 69,204 0.1 1 22,087 32.5 249,176 0.1 6 68,034 686,44 6-14 14,476 38.3 146,556 0.1 2 8,904 23.5 95,937 0.1 8 37,809 383,71 15-20 51,347 69.9 488,438 0.2 5 12,650 17.2 126,920 0.2 9 73,493 562,51 45-64 2.475 66.1 23,881 0.3 7 54 36.7 593 0.2 7 147 1.1 75-84 86 28.9 882 0.6 21 147 49.3 1,513 0.4 9 29.8 1.9 <													
5 and younger 1,804 3.1 20,118 0.1 1 24,140 40.9 259,288 0.1 4 59,050 545,91 6-14 6,147 9.1 69,924 0.1 1 22,087 32.5 249,176 0.1 8 37,809 338,71 15-20 51,347 69.9 488,438 0.2 5 12,650 17.2 126,920 0.2 9 73,493 562,51 21-44 2,475 65.1 23,861 0.3 10 787 20,7 8,087 0.2 13 3,804 29,7 45-64 44 29.9 452 0.3 7 54 36.7 593 0.2 7 147 1,15 65-74 86 28.9 882 0.6 21 147 49.3 1,513 0.4 9 298 1,91 75-84 86 26.9 825 0.2 9 56,629 25.6 649,037 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>=</td><td></td><td></td></th<>											=		
5 and younger 6,167 9.1 69,204 0.1 1 22,087 32.5 249,176 0.1 6 68,034 686,44 6-14 14,476 38.3 146,556 0.1 2 8,904 23.5 95,937 0.1 8 37,809 383,7 15-20 51,347 69.9 488,438 0.2 5 12,650 17.2 126,907 0.2 9 73,493 562,51 21-44 2,475 65.1 23,861 0.3 10 787 20.7 8,087 0.2 13 3,804 29,74 45-64 44 29.9 452 0.3 7 54 36.7 593 0.2 7 147 1,1 65-74 486 28.9 882 0.6 21 147 49.3 1,513 0.4 9 288 1,99 75-84 61 18.0 570,955 0.2 9 58,629 25.6 649,037	Other Eligibles	-,		,		•	·	_	-	• • • •	-	,	
6-14 14,476 38.3 146,556 0.1 2 8.904 23.5 95,937 0.1 8 37,809 338,715-20 51,347 69.9 488,438 0.2 5 12,650 17.2 126,920 0.2 9 73,493 562,51 45-64 24.75 65.1 23,861 0.3 10 787 20.7 8,087 0.2 13 3,804 29,77 45-64 44 29.9 452 0.3 7 54 36.7 593 0.2 7 147 1,11 1,11 1,11 1,11 1,11 1,11 1,1	5 and vounger	,				•	,		,			,	,
15-20	, ,	,		,			,		,			,	,
21-44				-,			- ,		-		_	· ·	
45-64		,					,		-				
65-74 86 28.9 882 0.6 21 147 49.3 1.513 0.4 9 298 1.9 75-84 61 18.0 574 0.4 11 131 38.8 1,308 0.3 6 338 1.6 85 and older Male 52,726 23.0 570,955 0.2 9 58,629 25.6 649,037 0.2 7 229,231 2,231,9 Disabled 27,497 51.6 313,607 0.3 13 14,016 26.3 162,598 0.2 9 53,262 576,33 238 9.6 2,764 0.1 1 1,182 47.8 13,809 0.1 4 2,471 26,81 5 and younger 1,056 11.9 12,447 0.1 1 2,791 31.6 33,067 0.1 5 8,843 100,4 6-14 1,842 29.9 21,431 0.2 3 1,566 25.5 18,333 0.2 9 6,151 67,54 11,579 66.2 132,223 0.3 10 3,778 21.6 43,737 0.2 11 17,478 189,55 21-44 12,648 70.0 143,377 0.3 17 4,606 25.5 52,653 0.2 12 18,056 189,4 45-64 108 49.5 1,088 0.5 28 71 32.6 753 0.3 8 218 1,96 65-74 23 60.5 245 0.3 16 19 50.0 210 0.3 13 38 44 55 and younger 6,111 8.8 68,526 0.1 1 21,286 33.9 227,937 0.1 4 62,824 578,6 61-14 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,2 21-44 1,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,2 21-44 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,2 21-44 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,2 21-44 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,2 21-44 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,2 21-44 1,257 56.9 11,875 0.3 13 312 14.1 3,103 0.2 13 2,211 16,96 21-44 1,257 56.9 11,875 0.3 13 312 14.1 3,103 0.2 13 2,211 16,96 21-44 1,257 56.9 11,875 0.3 13 312 14.1 3,103 0.2 12 12,776 95,77 21-44 29 38.8 921 0.8 37 202 85.2 2,158 0.3 7 237 1,86 25-74 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 237 1,86 25-74 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 233 1,77 25-84 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 233 1,77 25-84 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 233 1,77 25-84 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 233 1,77 25-84 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 233 1,77 25-84 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 233 1,77 25-84 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 233 1,77 25-84 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 233 1,77 25-84 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 233 1,77 25-84 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 233		,		,								,	,
75-84 66 28.9 682 0.6 21 147 49.3 1,513 0.4 9 296 1,91 85 and older Male 52,726 23.0 570,955 0.2 9 58,629 25.6 649,037 0.2 7 229,231 2,231,92 Disabled 27,497 51.6 313,607 0.3 13 14,016 26.3 162,598 0.2 9 53,262 576,33 238 9.6 2,764 0.1 1 1,182 47.8 13,809 0.1 4 2,471 26,81 5 and younger 1,056 11.9 12,447 0.1 1 2,791 31.6 33,067 0.1 5 8,843 100,4 6-14 1,842 29.9 21,431 0.2 3 1,566 25.5 18,333 0.2 9 6,151 67,55 15-20 11,579 66.2 132,223 0.3 10 3,778 21.6 43,737 0.2 11 17,478 189,55 21-44 12,648 70.0 143,377 0.3 17 4,606 25.5 52,653 0.2 12 18,056 189,4 45-64 108 49.5 1,088 0.5 28 71 32.6 753 0.3 8 218 1,9 65-74 23 60.5 245 0.3 16 19 50.0 210 0.3 13 38 44 65-74 23 60.5 245 0.3 16 19 50.0 210 0.3 13 38 4 85 and older 25 29 14.3 257,348 0.2 4 44,611 25.4 486,415 0.1 6 175,969 1,655,55 5 and younger 6,111 8.8 68,526 0.1 1 21,286 33.9 227,937 0.1 4 62,824 578,66 5 and younger 6,111 8.8 68,526 0.1 1 12,487 22.3 174,697 0.1 5 69,135 695,55 6-14 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,22 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 28,430 264,22 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 28,430 264,22 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 28,430 264,22 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 12,776 95,77 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 12,776 95,77 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 12,776 95,77 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 12,776 95,77 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 12,776 95,77 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 12,776 95,77 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 12,776 95,77 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 12,284 30 264,27 15-20 8,410 65.8 76,974 0.2 8 1,583 12 12.0 14,800 0.2 12 12,2776 95,77 15-24 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 22 12 123 77,800 1 12 12 12 12 12 12 12 12 12 12 12 12 1			29.9		0.3				593				,
85 and older Male 52,726 23.0 577,955 0.2 9 58,629 25.6 649,037 0.2 7 229,231 2,231,9 Disabled 27,497 51.6 313,607 0.3 13 14,016 26.3 162,598 0.2 9 53,262 576,31 5 and younger 1,056 11.9 12,447 0.1 1 2,791 31.6 33,067 0.1 5 8,843 100,4 6-14 1,842 29.9 21,431 0.2 3 1,566 25.5 18,333 0.2 9 6,151 67,51 15-20 11,579 66.2 133,223 0.3 10 3,778 21.6 43,737 0.2 11 17,478 189,55 21-44 12,648 70.0 143,377 0.3 17 4,606 25.5 52,653 0.2 12 189,44 45-64 108 49.5 1,088 0.5 28 71		86	28.9	882	0.6	21	147	49.3	1,513	0.4	9	298	1,996
Male 52,726 23.0 570,955 0.2 9 58,629 25.6 649,037 0.2 7 229,231 2,231,90 Disabled 27,497 51.6 313,607 0.3 13 14,016 26.3 162,598 0.2 9 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,319 53,262 576,271 53,262 576,271 53,262 576,271 53,262 576,271 53,262 <		61	18.0	574	0.4	11	131	38.8	1,308	0.3	6	338	1,606
Disabled 27,497 51.6 313,607 0.3 13 14,016 26.3 162,598 0.2 9 53,262 576,33 576,33 53 14,016 26.3 162,598 0.2 9 53,262 576,33 576,33 53 47.8 13,809 0.1 4 2,471 26,81 26,81 276,41 0.1 1 1,182 47.8 13,809 0.1 4 2,471 26,81 26,81 26,81 27,91 31.66 25.5 133,3067 0.1 5 8,843 100,4 46,61 132,223 0.3 10 3,778 21.6 43,737 0.2 11 17,478 189,55 18,333 0.2 9 6,151 69,55 15,56 15,56 25.5 18,333 0.2 9 6,151 67,55 15,56 143,377 0.3 17 4,606 25.5 52,653 0.2 12 18,056 189,4 45,64 45,64 108 49,5 13,88 <td></td> <td>E2 726</td> <td>22.0</td> <td>E70 0EE</td> <td>0.2</td> <td>0</td> <td>E0 600</td> <td>25.6</td> <td>640.027</td> <td>0.2</td> <td>7</td> <td>220 224</td> <td>2 224 045</td>		E2 726	22.0	E70 0EE	0.2	0	E0 600	25.6	640.027	0.2	7	220 224	2 224 045
5 and younger 238 9.6 2,764 0.1 1 1,182 47.8 13,809 0.1 4 2,471 26,81 6-14 1,056 11.9 12,447 0.1 1 2,791 31.6 33,067 0.1 5 8,843 100,47 6-14 1,842 29.9 21,431 0.2 3 1,566 25.5 18,333 0.2 9 6,151 67,57 15-20 11,579 66.2 132,223 0.3 10 3,778 21.6 43,737 0.2 11 17,478 189,57 21-44 12,648 70.0 143,377 0.3 17 4,606 25.5 52,653 0.2 12 18,056 189,4 45-64 108 49.5 1,088 0.5 28 71 32.6 753 0.3 8 218 1,9 65-74 23 60.5 245 0.3 16 19 50.0 210		,					,		,			,	
5 and younger 1,056 11.9 12,447 0.1 1 2,791 31.6 33,067 0.1 5 8,843 100,4 6-14 1,842 29.9 21,431 0.2 3 1,566 25.5 18,333 0.2 9 6,151 67,57 15-20 11,579 66.2 132,223 0.3 10 3,778 21.6 43,737 0.2 11 17,478 189,55 21-44 12,648 70.0 143,377 0.3 17 4,606 25.5 52,653 0.2 12 18,056 189,4 45-64 108 49.5 1,088 0.5 28 71 32.6 753 0.3 8 218 1,99 65-74 23 60.5 245 0.3 16 19 50.0 210 0.3 13 38 44 75-84 3 42.9 32 0.1 2 3 42.9 36 0.1	Disabled	,					,		,			,	
6-14	5 and vounger			, -					-				
15-20		,					,		,			,	
21-44		,		,			,		,			,	•
45-64 10.8 49.5 1,088 0.5 28 71 32.6 753 0.3 8 218 1,98 65-74 23 60.5 245 0.3 16 19 50.0 210 0.3 13 38 44 75-84 3 42.9 32 0.1 2 3 42.9 36 0.1 1 7 0.6 85 and younger 6,111 8.8 68,526 0.1 1 15,437 22.3 174,697 0.1 5 69,135 695,53 6-14 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,29 15-20 8,410 65.8 76,974 0.2 8 1,532 12.0 14,800 0.2 12 12,776 95,79 14,564 1,257 56.9 11,875 0.3 13 312 14.1 3,103 0.2 13 2,211 16,96 65-74 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 237 1,856 51 1,74 85 and older				- , -			,					,	,
65-74 23 60.5 245 0.3 16 19 50.0 210 0.3 13 38 44 75-84 33 42.9 36 0.1 1 7 6 6 75-84 85 and older 25,229 14.3 257,348 0.2 4 44,611 25.4 486,415 0.1 6 175,969 1,655,500		,					,						·
75-84				,		_							,
85 and older Other Eligibles 25,229 14.3 257,348 0.2 4 44,611 25.4 486,415 0.1 6 175,969 1,655,58 5 and younger 6,111 8.8 68,526 0.1 1 15,437 22.3 174,697 0.1 5 69,135 695,55 6-14 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,29 15-20 8,410 65.8 76,974 0.2 8 1,532 12.0 14,800 0.2 12 28,430 264,29 21-44 1,257 56.9 11,875 0.3 13 312 14.1 3,103 0.2 12 12,776 95,79 45-64 53 43.1 555 0.5 30 57 46.3 589 0.2 12 123 78 65-74 92 38.8 921 0.8 37 202 85.2 </td <td></td>													
5 and younger 6,111 8.8 68,526 0.1 1 15,437 22.3 174,697 0.1 5 69,135 695,53 6-14 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,29 15-20 8,410 65.8 76,974 0.2 8 1,532 12.0 14,800 0.2 12 12,776 95,79 1-44 1,257 56.9 11,875 0.3 13 312 14.1 3,103 0.2 13 2,211 16,96 65-74 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 237 1,88 75-84 91 39.1 918 0.7 29 199 85.4 2,031 0.3 7 233 1,74 85 and older											-		
5 and younger 6,111 8.8 68,526 0.1 1 15,437 22.3 174,697 0.1 5 69,135 695,55 6-14 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,25 15-20 8,410 65.8 76,974 0.2 8 1,532 12.0 14,800 0.2 12 12,776 95,75 21-44 1,257 56.9 11,875 0.3 13 312 14.1 3,103 0.2 13 2,211 16,96 45-64 53 43.1 555 0.5 30 57 46.3 589 0.2 12 123 78 65-74 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 237 1,85 75-84 91 39.1 918 0.7 29 199 85.4 2,031 0.3 7 233 1,74 85 and older	Other Eligibles	,					,		,			,	
6-14 6,699 23.6 69,757 0.1 2 5,586 19.6 61,100 0.2 12 28,430 264,29 15-20 8,410 65.8 76,974 0.2 8 1,532 12.0 14,800 0.2 12 12,776 95,79 21-44 1,257 56.9 11,875 0.3 13 312 14.1 3,103 0.2 13 2,211 16,96 45-64 53 43.1 555 0.5 30 57 46.3 589 0.2 12 123 78 65-74 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 237 1,88 75-84 91 39.1 918 0.7 29 199 85.4 2,031 0.3 7 233 1,74 85 and older	5 and younger	,		,			,		,			,	
15-20 8,410 65.8 76,974 0.2 8 1,532 12.0 14,800 0.2 12 12,776 95,78 21-44 1,257 56.9 11,875 0.3 13 312 14.1 3,103 0.2 13 2,211 16,96 45-64 53 43.1 555 0.5 30 57 46.3 589 0.2 12 123 78 65-74 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 237 1,88 75-84 91 39.1 918 0.7 29 199 85.4 2,031 0.3 7 233 1,74 85 and older	, ,	- /		,			-, -					,	
21-44 1,257 56.9 11,875 0.3 13 312 14.1 3,103 0.2 13 2,211 16,96 45-64 53 43.1 555 0.5 30 57 46.3 589 0.2 12 123 78 65-74 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 237 1,85 75-84 91 39.1 918 0.7 29 199 85.4 2,031 0.3 7 233 1,74 85 and older		,					,						·
45-64 53 43.1 555 0.5 30 57 46.3 589 0.2 12 123 78 65-74 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 237 1,85 75-84 91 39.1 918 0.7 29 199 85.4 2,031 0.3 7 233 1,74 85 and older		,					,		,				·
65-74 92 38.8 921 0.8 37 202 85.2 2,158 0.3 7 237 1,85 75-84 91 39.1 918 0.7 29 199 85.4 2,031 0.3 7 233 1,74 85 and older		,			0.3				,			,	16,960
75-84 91 39.1 918 0.7 29 199 85.4 2,031 0.3 7 233 1,74 85 and older		53	43.1	555	0.5	30	57	46.3	589	0.2	12	123	_
85 and older		92	38.8	921	8.0	37	202	85.2	2,158	0.3	7	_	1,857
		91	39.1	918	0.7	29	199	85.4	2,031	0.3	7	233	1,741
LINKNOWN 1 37 6 15 13 5 186 66 01 // 97 97	85 and older Unknown	1	3.7	6	1.5	13	5	18.5	56	0.1	4	27	227

Table ND7D Nondual Beneficiaries

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

Table ND7D Nondual Beneficiaries

TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC $^{a,\,b}$

NONDUAL BENEFICIARIES, KENTUCKY, 2004

Beneficiary Characteristics	Rx \$ per Benefit Month	Number of Rx per Benefit Month	Number of All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	\$641	11.9	1,128	11,271
Age				
0-64	724	12.9	769	7,802
65-74	634	12.0	67	655
75-84	465	9.4	140	1,406
85 and older	358	8.7	152	1,408
Unknown	0	0.0	0	0
Gender				
Female	667	12.3	596	5,934
Male	612	11.5	532	5,337
Unknown	0	0.0	0	0
Race				
White	631	11.9	899	8,905
African American	602	11.3	123	1,269
Other/unknown	768	12.7	106	1,097
Basis of Eligibility ^c				
Aged	417	9.2	307	2,959
Disabled	719	12.9	807	8,242
Adults	2,099	15.8	10	22
Children	445	8.7	4	48
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2004 file for Kentucky, released by CMS in 02/2008. This table was produced on 03/06/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2004 Medicaid enrollment. A total of 3,058 beneficiaries who were in nursing facilities for part of their enrollment and their 31,329 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORY NONDUAL BENEFICIARIES, KENTUCKY, 2004

		er of Ro	ong Use			er Bene Among	Users	th		\$ per						Users	
Therapeutic Category	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total Number of Rx	Total Rx \$	P Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.6	0.3	0.0	0.3	\$52	\$37	\$3	\$11	\$85	\$136	\$81	\$39	5,567	\$473,664	866	76.8 %	9,122
Biologicals	0.1	0.1	0.0	0.0	14	2	11	1	143	33	2,906	31	78	11,135	69	6.1	797
Antineoplastic Agents	8.0	0.0	0.0	0.7	81	22	0	59	107	951	123	80	897	95,879	119	10.5	1,177
Endocrine/Metabolic Drugs	1.3	0.6	0.2	0.5	64	50	5	9	51	83	26	19	7,937	402,689	602	53.4	6,274
Cardiovascular Agents	2.2	0.6	0.1	1.6	64	35	2	28	29	63	24	17	17,105	498,346	764	67.7	7,733
Respiratory Agents	1.2	0.5	0.0	0.7	56	38	1	16	47	82	33	24	9,247	437,507	746	66.1	7,845
Gastrointestinal Agents	1.6	0.5	0.1	1.0	68	46	4	18	43	97	34	18	13,073	561,383	791	70.1	8,262
Genitourinary Agents	1.0	0.3	0.0	0.6	91	25	2	64	93	78	55	103	3,807	354,053	366	32.4	3,872
CNS Drugs	3.0	1.1	0.1	1.7	165	129	8	28	55	114	56	16	27,843	1,534,465	907	80.4	9,323
Stimulants/Anti-obesity/Anorexia	0.7	0.4	0.0	0.3	42	38	0	4	61	99	0	14	140	8,526	20	1.8	201
Miscellaneous Psychological/							_	_				_					
Neurological Agents	0.9	0.9	0.0		144	144	0	_	161	161	0	0	1,453	234,238	161	14.3	1,626
Analgesics and Anesthetics	1.5	0.4	0.0	-	62	46	1	15	42	106	14	15	10,971	456,288	708	62.8	7,357
Neuromuscular Agents	2.2	0.4	0.3	1.5	148	68	30	50	67	165	91	34	15,858	1,061,163	668	59.2	7,182
Nutritional Products	1.0	0.0	0.0	1.0	25	1	1	24	25	93	33	24	5,241	131,171	511	45.3	5,153
Hematological Agents	1.3	0.5	0.0	8.0	127	115	1	11	96	214	64	14	5,723	549,498	437	38.7	4,342
Topical Products	8.0	0.2	0.1	0.5	31	17	4	11	37	74	39	21	7,278	268,645	803	71.2	8,600
Miscellaneous Products	0.7	0.0	0.0	0.7	59	0	0	58	85	12	200	88	1,596	135,498	215	19.1	2,294
Unknown Therapeutic Category	0.5	0.0	0.0	0.0	12	0	0	0	25	0	0	0	432	10,624	83	7.4	920
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	134,246	7,224,772	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Kentucky, released by CMS in 02/2008. This table was produced on 03/06/2008.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 3,058 beneficiaries who were in nursing facilities for part of their enrollment and their 31,329 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In Kentucky, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND9 Nondual Beneficiaries

TABLE ND.10

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP-10 DRUG GROUP^{a, b, c, d}

NONDUAL BENEFICIARIES, KENTUCKY, 2004

			Users			Among Users	
			As a Percentage of All-Year				
		Number of	Nursing Facility	Number of	Number of Rx per		Rx \$ per Benefit
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Users	Residents	Benefit Months	Benefit Month	\$ per Rx	Month
ANTIPSYCHOTICS	\$903,180	605	53.6 %	6,577	0.8	\$169	\$137
ANTICONVULSANT	770,585	788	69.9	8,673	1.4	65	89
ANTIDEPRESSANTS	471,113	874	77.5	9,154	1.1	46	51
ULCER DRUGS	407,565	806	71.5	8,457	0.8	58	48
ANTIASTHMATIC	331,262	830	73.6	8,613	0.7	58	38
HEMATOPOIETIC AGENTS	278,787	436	38.7	4,424	0.8	75	63
ANALGESICS - Narcotic	262,459	711	63.0	7,262	1.0	36	36
MISCELLANEOUS GENITOURINARY							
PRODUCTS	254,497	181	16.0	1,911	1.1	118	133
DERMATOLOGICAL	237,342	2,344	207.8	25,427	0.4	25	9
MISC PSYCHOTHERAPEUTIC AND							
NEUROLOGICAL	230,126	188	16.7	1,928	0.8	159	119
Total	4,146,916	7,763		82,426	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Kentucky, released by CMS in 02/2008. This table was produced on 03/06/2008.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 3,058 beneficiaries who were in nursing facilities for part of their enrollment and their 31,329 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST

AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}

NONDUAL BENEFICIARIES, KENTUCKY, 2004

	All Top 10 Dru	ug Groups		ANTIPS	SYCHOTICS			ANTICONVULSANT				
Beneficiary			Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Amona	Mean Number	Mean	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean
Characteristics	Number of Rx	Rx \$	Users	Residents	Users	of Rx	Rx\$	Users	Residents	Users	of Rx	Rx\$
All	64,259	\$4,146,916	605	53.6 %	6,577	0.8	\$137	788	69.9 %	8,673	1.4	\$89
Female	35,225	2,392,308	338	56.7	3,654	0.8	142	459	77.0	5,093	1.4	94
Disabled	30,217	2,123,939	276	60.0	3,043	8.0	153	409	88.9	4,554	1.4	98
04	28,444	2,007,058	247	57.8	2,714	0.9	161	400	93.7	4,446	1.4	99
64 or younger	1,430	94,159	19	82.6	220	0.6	79	8	34.8	96	0.7	58
65-74	292	19,161	10	125.0	109	0.8	80	0	0.0	0	0.0	0
75-84	51	3,561	0	0.0	0	0.0	0	1	50.0	12	1.0	152
85 and older Other Eligibles	5,008	268,369	62	45.6	611	0.7	91	50	36.8	539	1.2	57
J	140	6,394	0	0.0	0	0.0	0	4	44.4	48	2.4	110
64 or younger	744	45,182	10	58.8	109	1.1	139	13	76.5	154	1.2	50
65-74	2,163	121,794	23	44.2	226	0.7	101	16	30.8	172	1.0	53
75-84	1,961	94,999	29	50.0	276	0.5	63	17	29.3	165	1.0	51
85 and older	00.004	4 75 4 000	207	50.0	0.000	0.0	404	200	04.0	0.500		00
Male	29,034	1,754,608	267	50.2	2,923	0.8	131	329	61.8	3,580	1.4	82
Disabled	21,141	1,284,714	174	50.1	1,953	8.0	144	262	75.5	2,864	1.5	88
64 or younger	19,956	1,218,515	163	49.8	1,831	8.0	145	250	76.5	2,749	1.5	90
65-74	734	35,280	5	41.7	50	0.4	48	6	50.0	54	1.7	36
75-84	450	30,888	6	85.7	72	0.9	184	5	71.4	60	1.2	41
85 and older	1	31	0	0.0	0	0.0	0	1	100.0	1	1.0	31
Other Eligibles	7,893	469,894	93	50.3	970	0.8	106	67	36.2	716	0.9	55
64 or younger	203	22,591	1	16.7	1	1.0	28	6	100.0	61	0.8	110
65-74	875	66,649	15	100.0	172	0.6	103	11	73.3	115	0.8	70
75-84	3,602	220,293	46	63.0	495	8.0	124	33	45.2	355	1.0	57
85 and older	3,213	160,361	31	34.1	302	0.7	80	17	18.7	185	0.6	25
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 3,058 beneficiaries who were in nursing facilities for part of their enrollment and their 31,329 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, KENTUCKY, 2004

	ANTIDEPRESSANTS						ULCE	R DRUGS			ANTIASTHMATIC				
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Users	of Rx	Mean Rx \$
All	874	77.5 %	9,154	1.1	\$52	806	71.5 %	8,457	8.0	\$48	830	73.6 %	8,613	0.7	\$39
Female	508	85.2	5,315	1.1	51	411	69.0	4,248	0.8	47	433	72.7	4,471	0.7	43
Disabled	402	87.4	4,240	1.2	52	330	71.7	3,425	0.9	50	374	81.3	3,851	0.7	45
r 64 or younge	374	87.6	3,927	1.2	52	302	70.7	3,124	0.9	52	338	79.2	3,504	0.7	39
65-74	22	95.7	254	1.2	56	21	91.3	228	0.7	39	27	117.4	261	0.9	125
75-84	5	62.5	49	1.1	65	7	87.5	73	0.6	11	8	100.0	74	0.6	28
	1	50.0	10	0.2	5	0	0.0	0	0.0	0	1	50.0	12	1.1	98
85 and older Other Eligibles	106	77.9	1,075	1.0	46	81	59.6	823	0.7	32	59	43.4	620	0.5	28
r 64 or younge	0	0.0	0	0.0	0	1	11.1	12	1.3	85	1	11.1	12	0.1	1
65-74	16	94.1	155	0.9	48	12	70.6	112	0.8	56	4	23.5	36	0.6	27
75-84	39	75.0	391	1.1	50	28	53.8	288	0.7	30	27	51.9	308	0.5	38
85 and older	51	87.9	529	0.9	43	40	69.0	411	0.6	25	27	46.6	264	0.5	17
Male	366	68.8	3,839	1.1	52	395	74.2	4,209	0.8	50	397	74.6	4,142	0.7	34
Disabled	238	68.6	2,514	1.1	52	279	80.4	2,968	0.9	53	284	81.8	3,023	0.7	35
r	227	69.4	2,396	1.1	52	259	79.2	2,762	0.9	53	263	80.4	2,795	0.6	32
64 or younge	7	58.3	70	0.9	43	13	108.3	130	0.7	56	16	133.3	172	1.3	71
65-74 75-84	4	57.1	48	1.7	81	7	100.0	76	0.9	54	5	71.4	56	1.1	67
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	128	69.2	1,325	1.1	52	116	62.7	1,241	0.7	42	113	61.1	1,119	0.6	32
r	0	0.0	0	0.0	0	2	33.3	24	8.0	128	4	66.7	48	0.7	33
64 or younge 65-74	12	80.0	132	1.4	78	10	66.7	105	0.6	22	8	53.3	60	0.6	30
75-84	59	80.8	628	1.1	53	50	68.5	544	0.7	38	47	64.4	523	0.5	28
85 and older	57	62.6	565	1.0	46	54	59.3	568	0.7	45	54	59.3	488	0.8	36
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Kentucky, released by CMS in 02/2008. This table was produced on 03/06/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit: \$ = Medicaid reimbursement.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 3,058 beneficiaries who were in nursing facilities for part of their enrollment and their 31,329 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, KENTUCKY, 2004

		HEMATOPO	DIETIC AGEN	NTS			ANALGES	SICS - Narcot	ic		MISCELLA	MISCELLANEOUS GENITOURINARY PRODUCTS				
Beneficiary Characteristics	Number of Users 436	Users as % of All-Year Nursing Facility Residents 38.7 %	Number of Benefit Months Among Users 4,424	Mean Number of Rx	Mean Rx \$	Number of Users 711	Users as % of All-Year Nursing Facility Residents 63.0 %	Number of Benefit Months Among Users 7,262	Mean Number of Rx	Mean Rx \$	Number of Users 181	Users as % of All-Year Nursing Facility Residents 16.0 %	Number of Benefit Months Among Users 1,911	Mean Number of Rx 1.1	Mean Rx \$ \$133	
			•													
Female	239	40.1	2,412	0.9	90	381	63.9	3,845	1.0	32	75	12.6	781	1.2	159	
Disabled	195	42.4	1,945	0.9	102	316	68.7	3,197	1.0	34	61	13.3	644	1.3	186	
r 64 or younge	180	42.2	1,797	1.0	110	294	68.9	2,959	1.1	35	58	13.6	617	1.4	194	
65-74	15	65.2	148	0.7	8	22	95.7	238	0.7	21	3	13.0	27	0.2	1	
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	
85 and older Other Eligibles	0	0.0	0 467	0.0	0 39	0 65	0.0 47.8	0 648	0.0 0.7	0 21	0	0.0 10.3	0 137	0.0	0	
Other Eligibles	44	32.4 0.0		0.8 0.0	39 0	2	47.8 22.2	14	0.7	21 2	14	0.0	137	0.5 0.0	35 0	
64 or younge	0 6	35.3	0 71	0.0	6	4	23.5	31	0.3 0.5	7	0	5.9	12	1.0	84	
65-74	19	36.5	203	1.0	83	31	59.6	342	0.5	7 26	2	3.8	14	0.2	2	
75-84	19	36.5 32.8	193	0.7	6 6	28	59.6 48.3	261	0.9	∠6 16	11	3.o 19.0	111	0.2	34	
85 and older	19	32.0	193	0.7	O	20	40.3	201	0.6	10	- 11	19.0	111	0.5	34	
Male	197	37.0	2,012	0.7	31	330	62.0	3,417	1.1	41	106	19.9	1,130	1.1	115	
Disabled	111	32.0	1,160	8.0	40	235	67.7	2,510	1.1	40	79	22.8	866	1.0	114	
r C4 an r	101	30.9	1,058	8.0	44	222	67.9	2,382	1.1	41	75	22.9	833	1.0	117	
64 or younge 65-74	5	41.7	50	0.3	4	8	66.7	76	1.5	28	3	25.0	25	0.4	43	
75-84	5	71.4	52	0.5	3	5	71.4	52	0.5	10	1	14.3	8	2.1	27	
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	
85 and older Other Eligibles	86	46.5	852	0.7	17	95	51.4	907	1.0	44	27	14.6	264	1.3	118	
r 64 or younge	0	0.0	0	0.0	0	2	33.3	24	1.4	80	1	16.7	12	2.8	645	
65-74	6	40.0	64	0.8	35	13	86.7	135	1.1	57	6	40.0	58	0.8	50	
75-84	28	38.4	268	0.6	8	37	50.7	337	1.1	44	13	17.8	124	1.5	103	
85 and older	52	57.1	520	0.7	20	43	47.3	411	1.0	37	7	7.7	70	1.1	110	
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	

Source: Data for this table are from the MAX 2004 file for Kentucky, released by CMS in 02/2008. This table was produced on 03/06/2008.

- a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 3,058 beneficiaries who were in nursing facilities for part of their enrollment and their 31,329 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit: \$ = Medicaid reimbursement.

Table ND10C Nondual Beneficiaries

TABLE ND.10D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{6, b, c, d} NONDUAL BENEFICIARIES, KENTUCKY, 2004

		DERMA	TOLOGICAL			MISC PSYC	HOTHERAP	EUTIC AND N	NEUROLO	GICAL		
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	All-Year Nursing \ Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	2,344	207.8 %	25,427	0.4	\$9	188	16.7 %	1,928	8.0	\$119	1,128	11,271
Female Disabled	1,243 1,022	208.6 222.2	13,469 11,090	0.4 0.4	10 10	99 51	16.6 11.1	988 535	0.7 0.8	143 197	596 460	5,934 4,668
64 or younger 65-74	952 54 12	223.0 234.8 150.0	10,339 559 144	0.4 0.4 0.3	10 6 3	41 6 4	9.6 26.1 50.0	432 55 48	0.8 0.8 0.6	220 111 81	427 23 8	4,329 232 85
75-84 85 and older Other Eligibles	4 221	200.0 162.5	48 2,379	0.5 0.3	11 7	0 48	0.0 35.3	0 453	0.6 0.0 0.7	0	2 136	22 1,266
64 or younger 65-74	4 27 90	44.4 158.8 173.1	48 292 988	0.1 0.3 0.4	1 7 9	0 9 21	0.0 52.9 40.4	0 75 201	0.0 0.6 0.7	0 55 79	9 17 52	32 166 535
75-84 85 and older Male	100	172.4	1,051 11.958	0.4	6 9	18	31.0	177 940	0.8	92 94	58 532	533
Disabled	781 746	225.1 228.1	8,543 8,182	0.4 0.4	10 10	29 24	8.4 7.3	326 271	0.7 0.7	95 93	347 327	3,574 3,398
64 or younger 65-74 75-84	25 10	208.3 142.9	257 104	0.3	6 3	3 2	25.0 28.6	35 20	0.8	103 111	12 7	110 65
85 and older Other Eligibles	0 320 12	0.0 173.0 200.0	0 3,415 144	0.0 0.3 0.3	0 8 11	0 60 0	0.0 32.4 0.0	0 614 0	0.0 0.8 0.0	0 94 0	1 185 6	1 1,763 43
64 or younger 65-74 75-84	32 139	213.3 190.4	334 1,510	0.3 0.3	17 7	6 32	40.0 43.8	68 322	0.8 0.8	116 94	15 73	147 721
85 and older Unknown	137	150.5 0.0	1,427 0	0.4	7 0	22	24.2 0.0	224	0.7	87 0	91	852 0

Source: Data for this table are from the MAX 2004 file for Kentucky, released by CMS in 02/2008. This table was produced on 03/06/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 3,058 beneficiaries who were in nursing facilities for part of their enrollment and their 31,329 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.11

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}

KENTUCKY, 2004

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Pa Part D Excluded Rx	art D Excluded Rx \$ per Beneficiary	Total Part D Excluded Rx \$		Part D Excluded Rx as a Percentage of T All Nondual Rx \$	Total Number of Beneficiaries
All	232,147	43.7 %	2.1	1,102,545	\$36	\$18,867,784	\$17	4.4 %	531,006
Age									
5 and younger	57,652	45.8	1.3	163,459	20	2,486,373	15	6.6	125,913
6-14	62,046	41.3	1.1	171,411	22	3,252,287	19	4.9	150,227
15-20	27,209	35.9	1.0	77,168	20	1,493,289	19	4.2	75,863
21-44	51,844	41.5	2.3	286,625	42	5,277,334	18	4.2	124,942
45-64	32,313	62.1	7.2	375,969	117	6,061,081	16	3.8	51,992
65-74	460	55.8	10.0	8,233	118	97,320	12	4.7	825
75-84	347	55.3	17.1	10,725	181	113,212	11	8.2	627
85 and older	265	44.8	15.1	8,934	146	86,507	10	10.4	592
Unknown	11	44.0	0.8	21	15	381	18	3.8	25
Basis of Eligibility ^c									
Aged	656	46.9	14.7	20,529	149	208,207	10	8.6	1,399
Disabled	63,781	56.9	5.4	604,758	98	10,946,456	18	3.9	112,038
Adults	36,758	36.1	1.3	128,345	21	2,120,645	17	4.3	101,837
Children	130,862	41.5	1.1	348,620	18	5,586,966	16	5.9	315,366
Unknown	90	24.6	0.8	293	15	5,510	19	1.5	366
Gender									
Female	138,552	45.9	2.3	688,989	39	11,818,480	17	4.6	301,760
Male	93,594	40.8	1.8	413,532	31	7,049,095	17	4.2	229,244
Unknown	1	50.0	12.0	24	105	209	9	8.9	2
Race									
White	205,341	45.2	2.1	952,831	35	16,082,430	17	4.5	454,259
African American	11,292	26.7	1.1	44,740	16	687,664	15	3.7	42,223
Other/unknown	15,514	44.9	3.0	104,974	61	2,097,690	20	4.0	34,524
Use of Nursing Facilities ^d									
Entire year	1,088	96.5	57.1	64,361	694	782,769	12	10.8	1,128
Part year	2,450	80.1	12.9	39,430	200	610,465	15	4.5	3,058
None	228,609	43.4	1.9	998,754	33	17,474,550	17	4.3	526,820
Maintenance Assistance Status									
Cash	124,675	50.1	3.1	778,029	55	13,572,880	17	4.1	248,859
Medically needy	8,145	38.5	1.6	33,860	31	656,581	19	5.3	21,132
Poverty related	82,349	37.4	0.9	205,430	15	3,323,707	16	5.8	220,442
Other/unknown	16,978	41.8	2.1	85,226	32	1,314,616	15	4.8	40,573

Table ND11 Nondual Beneficiaries

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}

KENTUCKY, 2004

Beneficiary	Number Rx per	Rx \$ per		Barbiturate \$ per Ber	nzodiazepine \$ per	Number of
Characteristics	Benefit Month	Benefit Month	\$ per Rx	Benefit Month	Benefit Month	Benefit Months
All	0.2	\$4	\$17	\$0	\$1	5,047,400
Age						
5 and younger	0.1	2	15	0	0	1,168,426
6-14	0.1	2	19	0	0	1,530,277
15-20	0.1	2	19	0	0	709,280
21-44	0.3	5	18	0	1	1,084,582
45-64	0.7	11	16	0	2	539,045
65-74	1.1	13	12	0	2	7,265
75-84	2.2	24	11	0	3	4,804
85 and older	2.5	25	10	0	3	3,512
Unknown	0.1	2	18	0	0	209
Basis of Eligibility ^c						
Aged	2.2	22	10	0	3	9,343
Disabled	0.5	9	18	0	2	1,223,321
Adults	0.2	3	17	0	1	778,539
Children	0.1	2	16	0	0	3,035,019
Unknown	0.2	5	19	0	1	1,178
Gender						
Female	0.2	4	17	0	1	2,815,333
Male	0.2	3	17	0	1	2,232,049
Unknown	1.3	12	9	0	0	18
Race						
White	0.2	4	17	0	1	4,311,783
African American	0.1	2	15	0	0	398,888
Other/unknown	0.3	6	20	0	2	336,729
Use of Nursing						
Facilities ^d						
Entire year	5.7	69	12	2	18	11,271
Part year	1.3	19	15	0	6	31,329
None	0.2	3	17	0	1	5,004,800
Maintenance						
Assistance Status						
Cash	0.3	5	17	0	1	2,538,473
Medically needy	0.2	4	19	0	1	163,606
Poverty related	0.1	2	16	0	0	1,953,212
Other/unknown	0.2	3	15	0	0	392,109

Table ND12 Nondual Beneficiaries

- a. Table ND.12 includes the beneficaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c} KENTUCKY. 2004

	Rx \$ as a Percentage of All										
Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Part D Excluded Rx				
All	326,990	\$58	\$18,867,784	100.0 %	1,102,545	\$17	100.0 %				
Anorexia or weight loss/gain	133	175	23,275	0.1	378	62	0.0				
Fertility drugs	0	0	0	0.0	0	0	0.0				
Drugs for cosmetic purposes	11	9	103	0.0	11	9	0.0				
Cough and cold medications	116,926	36	4,171,505	22.1	216,690	19	19.7				
Vitamins and minerals	13,132	147	1,926,486	10.2	83,123	23	7.5				
Non-prescription drugs	155,375	46	7,209,417	38.2	574,952	13	52.1				
Barbiturates	1,844	67	122,750	0.7	18,158	7	1.6				
Benzodiazepines	23,670	144	3,407,885	18.1	151,616	22	13.8				
Other Part D Excl Rx Drugs	15,899	126	2,006,363	10.6	57,617	35	5.2				

Source: Data for this table are from the MAX 2004 file for Kentucky, released by CMS in 02/2008. This table was produced on 03/06/2008.

- a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2004. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.
- b. Includes OTC drugs as well as prescription drugs.
- c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

APPENDIX TABLE A.1
CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, KENTUCKY, 2004

Beneficiary			Number of Be	neficiaries				1	Number of Ben	efit Months		
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	676,814	1,626	134,630	128,075	412,115	368	6,450,718	11,589	1,478,829	984,004	3,975,084	1,212
Age												
5 and younger	166,961	1	5,548	18	161,394	0	1,555,962	12	60,617	111	1,495,222	0
6-14	196,228	0	17,184	32	179,012	0	2,003,030	0	196,649	228	1,806,153	0
15-20	96,607	0	12,177	13,456	70,973	1	905,402	0	135,637	100,048	669,715	2
21-44	153,803	4	45,368	107,510	680	241	1,332,962	36	500,890	827,717	3,622	697
45-64	60,819	25	53,595	7,050	24	125	634,302	229	577,600	55,851	113	509
65-74	1,036	398	632	6	0	0	9,431	3,211	6,184	36	0	0
75-84	702	597	104	1	0	0	5,554	4,478	1,069	7	0	0
85 and older	624	601	21	2	0	0	3,800	3,623	171	6	0	0
Unknown	34	0	1	0	32	1	275	0	12	0	259	4
Gender												
Female	385,444	938	70,052	110,980	203,106	368	3,604,789	6,275	776,184	856,291	1,964,827	1,212
Male	291,368	687	64,577	17,095	209,009	0	2,845,911	5,308	702,633	127,713	2,010,257	0
Unknown	2	1	1	0	0	0	18	6	12	0	0	0
Race												
White	538,181	1,248	97,002	105,987	333,599	345	5,105,217	8,294	1,063,456	818,149	3,214,210	1,108
African American	90,329	112	11,205	17,445	61,549	18	877,677	773	122,625	144,197	609,994	88
Other/unknown	48,304	266	26,423	4,643	16,967	5	467,824	2,522	292,748	21,658	150,880	16
Use of Nursing Facilities ^c												
Entire year	1,136	307	815	10	4	0	11,417	2,967	8,380	22	48	0
Part year	3,391	152	2,691	534	14	0	36,183	1,390	29,464	5,170	159	0
None	672,287	1,167	131,124	127,531	412,097	368	6,403,118	7,232	1,440,985	978,812	3,974,877	1,212
Maintenance Assistance Status												
Cash	310,252	379	130,410	63,509	115,954	0	3,172,101	3,881	1,451,731	538,518	1,177,971	0
Medically needy	26,047	264	2,601	12,754	10,428	0	207,821	1,669	11,539	92,466	102,147	0
Poverty related	288,466	17	22	35,160	252,899	368	2,563,852	164	178	205,544	2,356,754	1,212
Other/unknown	52,049	966	1,597	16,652	32,834	0	506,944	5,875	15,381	147,476	338,212	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	525,995	1,377	110,686	100,725	312,847	360	5,024,554	9,252	1,216,204	775,076	3,022,855	1,167
FFS part year, with Rx claims	2,809	14	1,044	460	1,287	4	30,561	157	11,765	4,373	14,237	29
FFS part year, no Rx claims	2,202	8	308	652	1,232	2	20,032	58	2,873	4,638	12,453	10
MC all year, with Rx claims	11,698	11	5,493	1,559	4,635	0	128,773	121	63,281	14,970	50,401	0
MC all year, no Rx claims	134,110	216	17,099	24,679	92,114	2	1,246,798	2,001	184,706	184,947	875,138	6

- a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2

MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a NONDUAL BENEFICIARIES, KENTUCKY, 2004

	Beneficiaries Benefit Months in Ce		Included in Cell K	of Table 1	Excluded from Cell	K of Table 1	
	Number of Nu Beneficiaries	mber of Benefit Months	Number of Nu Beneficiaries	mber of Benefit Months	Number of Number of Benefit Beneficiaries Months		
All	676,814	6,450,718	531,006	5,047,400	0	1,403,318	
Fee-for-service (FFS) all year	525,995	5,024,554	525,995	5,024,554	0	0	
FFS part year, with Rx claims	2,809	30,561	2,809	15,954	0	14,607	
FFS part year, with no Rx claims	2,202	20,032	2,202	6,892	0	13,140	
Managed care (MC) all year, with Rx claims	11,698	128,773	0	0	0	128,773	
MC all year, with no Rx claims	134,110	1,246,798	0	0	0	1,246,798	

Source: Data for this table are from the MAX 2004 file for Kentucky, released by CMS in 02/2008. This table was produced on 03/06/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.